Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by Lee430on Jan 10, 2021 11:45am
208 Views
Post# 32263186

RE:RE:The Ball is in THTX's Court

RE:RE:The Ball is in THTX's CourtReally with such great news from Thera I was hoping/expecting to end the week over $5, then next week we could see if there really is some pent-up institutional demand that could start to drive us back into double digits again…. My wife constantly reminds me to take baby steps soooo happy to celebrate $3 as a first step.



scarlet1967 wrote: I absolutely share that opinion the remarkable achievements to get NASH phase 3 soon to end line as per agencies approval of the protocol, starting the oncology platform in timely manner and increasing sales in the middle of pandemic when others have failed can't go unrecognized by the market so now they need to market it hard and effectively.
Attending as many conferences, using social media platforms, reaching out to fund managers etc etc is what this company needs to do so all these great achievements get noticed by the whole market.

longterm56 wrote: The waiting for other people and/or institutions is now over ... and what happens from here on is solely in the Thera's court.  We are no longer waiting on the NASH experts, the FDA, test results from NIH, papers being published ....  it is now all on Thera.

Some say we are waiting on the analysts to get it right, but they have spoken. They might be lazy or ignorant of the details of what Thera has, but that doesn't matter ...  the reason their reports are not supportive is because THEY ARE UNCONVINCED ... and the responsibility for changing that is solely on Thera. 

So ... Paul ... no pressure ... lol.

   -LT




<< Previous
Bullboard Posts
Next >>